Efficacy News and Research

RSS

BIOTRONIK introduces line extension to its popular 4 F compatible, self-expanding stent system

BIOTRONIK AG, a leading manufacturer of vascular interventional devices, announced the introduction of a line extension to its popular 4 F compatible, self-expanding stent system dedicated for the treatment of long disease segments in the superficial femoral artery (SFA) and infrapopliteal arteries.

18 Oct 2011

Study examines effectiveness of counseling approach for substance abuse among African-Americans

A new study is the first to examine the effectiveness of a widely used counseling approach to treating substance abuse among African-Americans. The study found that African-American women were more likely than men to continue a counseling approach to treating substance abuse, but their substance-abuse issues continued.

18 Oct 2011

HMS launches Initiative in Systems Pharmacology

Taking aim at the alarming slowdown in the development of new and lifesaving drugs, Harvard Medical School is launching an Initiative in Systems Pharmacology, a comprehensive strategy to transform drug discovery by convening biologists, chemists, pharmacologists, physicists, computer scientists and clinicians to explore together how drugs work in complex systems.

18 Oct 2011

Takeda commences TAK-875 Phase 3 clinical trial program for type 2 diabetes

Takeda Pharmaceutical Company Limited and its wholly-owned subsidiaries, Takeda Global Research & Development Center, Inc., and Takeda Global Research & Development Centre (Europe), Ltd., announced today the initiation of the Company's Phase 3 clinical trial program for TAK-875, an investigational therapy for type 2 diabetes.

18 Oct 2011

Natroba effective against head lice and nits

ParaPRO, LLC, announced that researchers have presented data showing the effectiveness of Natroba (spinosad) Topical Suspension, 0.9% against head lice and nits following one treatment without nit combing. Those data about the pediculicide, derived from a naturally-occurring soil bacterium, were presented in a poster session on Saturday, Oct. 15, 2011 at the American Academy of Pediatrics National Conference and Exhibition in Boston.

18 Oct 2011

Dendreon initiates enrollment in DN24-02 Phase 2 trial for HER2 positive cancer

Dendreon Corporation today announced that the company has begun enrolling patients into a Phase 2 trial for DN24-02, Dendreon's investigational active cellular immunotherapy being evaluated for the treatment of HER2 positive cancer.

18 Oct 2011

Gut bacteria shown to affect statin efficacy in some people

The team led by a Duke University scientist has identified three bile acids produced by gut bacteria that were evident in people who responded well to a common cholesterol-lowering drug called simvastatin. The finding, published Oct. 13, 2011, in PLoS One, demonstrates how gut bacteria can cause inherent differences in the way people digest, metabolize and benefit from substances such as drugs.

17 Oct 2011

NIH grants support SUNY's neuroscience, pediatric pharmacology and vision research

The State University of New York has received two grants totaling more than $4.3 million from the National Institutes of Health (NIH) to support neuroscience and pediatric pharmacology and vision research as part of SUNY REACH, a collaborative research network of SUNY's four academic health centers and the College of Optometry.

15 Oct 2011

Overweight children more likely to develop asthma

Asthma is considered one of the main causes of school absenteeism and its prevalence has risen in the last decades. Overweight children have been shown to have double the frequency of asthma than that of non-obese children.

15 Oct 2011

NextBio predicts mechanisms underlying drug toxicity and identifies new cancer biomarker

New research presented this week highlights the ability of NextBio to help life scientists and clinicians investigate publicly available genomic data to assess biological mechanisms underlying drug toxicity, as well as discover prospective cancer biomarkers for further validation.

15 Oct 2011

FDA approves PLC's U.S. pivotal trial of RenalGuard to prevent Contrast-Induced Nephropathy

PLC Systems Inc., a company focused on innovative medical device technologies, announced today that it has received final approval from the U.S. Food and Drug Administration to commence its U.S. pivotal trial to study the efficacy of the Company's RenalGuard Therapy and RenalGuard System in the prevention of Contrast-Induced Nephropathy.

14 Oct 2011

FDA's Circulatory System Devices Panel unanimously recommends Cook Medical's Zilver PTX Drug-Eluting Stent

The Zilver PTX Drug-Eluting Stent, the first device of its kind developed to treat peripheral artery disease (PAD) in the superficial femoral artery (SFA), has received a unanimous recommendation from the Food and Drug Administration's (FDA) Circulatory System Devices Panel of the Medical Devices Advisory Committee, Cook Medical announced today.

14 Oct 2011

Four companies receive NIAID contracts to develop broad-spectrum therapeutics

Four companies are to develop broad-spectrum therapeutics-antibiotics, antivirals and an antitoxin-to prevent or treat diseases caused by multiple types of bacteria or viruses, under contracts awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

14 Oct 2011

Merck announces results from ISENTRESS Phase III combination study on HIV-1

Merck, known as MSD outside the United States and Canada, today announced results of new exploratory pre-specified analyses from the ongoing STARTMRK Phase III study of its integrase inhibitor ISENTRESS (raltegravir) Tablets in combination therapy compared to efavirenz in combination therapy in previously untreated adult HIV-1-infected patients.

14 Oct 2011

Micromet receives FDA feedback on blinatumomab registration for R/R ALL

Micromet, Inc. today outlined a clinical development plan intended to support U.S. registration of its lead product candidate blinatumomab in patients with B-precursor relapsed/refractory (r/r) acute lymphoblastic leukemia.

14 Oct 2011

BCL11A protein might serve as potential target for sickle cell disease

Flipping a single molecular switch can reverse illness in a model of sickle cell disease, according to a study by researchers at Children's Hospital Boston and Dana-Farber Cancer Institute. When turned off, the switch, a protein called BCL11A, allows the body to manufacture red blood cells with an alternate form of hemoglobin unaffected by the mutation that causes the disease.

14 Oct 2011

Cylene advances preclinical development of CX-5461 for treatment of cancer

Cylene Pharmaceuticals, Inc. has advanced its targeted, non-genotoxic, activator of p53 for the treatment of leukemias, lymphomas and multiple myeloma through formal preclinical development, the Company announced today.

14 Oct 2011

Hydromorphone can be as effective as diacetylmorphine in treating heroin addiction

A clinical trial to test better treatment options for chronic heroin addiction is expected to begin in Vancouver at the end of this year. Led by researchers from Providence Health Care and the University of British Columbia, it's the only clinical trial of its kind in North America.

13 Oct 2011

Autism Speaks announces 10 new research grants

Autism Speaks, the world's largest autism science and advocacy organization, today announced the awarding of 10 new research grants totaling $1,782,934 in funding over the next three years. The selected studies will evaluate the effectiveness of a broad array of promising behavioral and medical treatments for core symptoms and associated medical issues in children, adolescents, and adults with autism spectrum disorders.

13 Oct 2011

EMA recommends 4SC's resminostat for orphan medicinal product designation to treat HL

4SC AG, a discovery and development company of targeted small molecule drugs for autoimmune diseases and cancer, today announced that the European Medicines Agency (EMA) has recommended 4SC's anti-cancer compound resminostat for designation as orphan medicinal product for the treatment of Hodgkin's Lymphoma (HL), a cancer of the lymphatic system.

13 Oct 2011

Efficacy News and Research

BIOTRONIK introduces line extension to its popular 4 F compatible, self-expanding stent system

Study examines effectiveness of counseling approach for substance abuse among African-Americans

HMS launches Initiative in Systems Pharmacology

Takeda commences TAK-875 Phase 3 clinical trial program for type 2 diabetes

Natroba effective against head lice and nits

Dendreon initiates enrollment in DN24-02 Phase 2 trial for HER2 positive cancer

Gut bacteria shown to affect statin efficacy in some people

NIH grants support SUNY's neuroscience, pediatric pharmacology and vision research

Overweight children more likely to develop asthma

NextBio predicts mechanisms underlying drug toxicity and identifies new cancer biomarker

FDA approves PLC's U.S. pivotal trial of RenalGuard to prevent Contrast-Induced Nephropathy

FDA's Circulatory System Devices Panel unanimously recommends Cook Medical's Zilver PTX Drug-Eluting Stent

Four companies receive NIAID contracts to develop broad-spectrum therapeutics

Merck announces results from ISENTRESS Phase III combination study on HIV-1

Micromet receives FDA feedback on blinatumomab registration for R/R ALL

BCL11A protein might serve as potential target for sickle cell disease

Cylene advances preclinical development of CX-5461 for treatment of cancer

Hydromorphone can be as effective as diacetylmorphine in treating heroin addiction

Autism Speaks announces 10 new research grants

EMA recommends 4SC's resminostat for orphan medicinal product designation to treat HL

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News